GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Cash, Cash Equivalents, Marketable Securities

Anavex Life Sciences (STU:12X1) Cash, Cash Equivalents, Marketable Securities : €128.24 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Cash, Cash Equivalents, Marketable Securities?

Anavex Life Sciences's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (€141.51 Mil) to Dec. 2023 (€131.83 Mil) but then stayed the same from Dec. 2023 (€131.83 Mil) to Mar. 2024 (€128.24 Mil).

Anavex Life Sciences's annual cash, cash equivalents, marketable securities increased from Sep. 2021 (€129.29 Mil) to Sep. 2022 (€150.65 Mil) but then declined from Sep. 2022 (€150.65 Mil) to Sep. 2023 (€141.51 Mil).


Anavex Life Sciences Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Anavex Life Sciences's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Cash, Cash Equivalents, Marketable Securities Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.15 24.83 129.29 150.65 141.51

Anavex Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.34 142.90 141.51 131.83 128.24

Anavex Life Sciences Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Anavex Life Sciences  (STU:12X1) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Anavex Life Sciences Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (STU:12X1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines